Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Previous Page Next Page

On-target AEs management

Key physiological processes controlled by the TRK pathway include appetite, balance, and pain sensitivity. Consequently, TRK inhibitors are associated with a relatively unique set of on-target adverse events (AEs) that are unlike AEs seen with other anticancer therapies. These AEs remain under-recognized, and pain upon drug withdrawal has not been previously reported. As such, TRK-associated AEs warrant careful monitoring and management [1].

References

  1. Liu D, Flory J, Lin A, Offin M, Falcon CJ, Murciano-Goroff YR, Rosen E, Guo R, Basu E, Li BT, Harding JJ, Iyer G, Jhaveri K, Gounder MM, Shukla NN, Roberts SS, Glade-Bender J, Kaplanis L, Schram A, Hyman DM, Drilon A. Characterization of on-target adverse events caused by TRK inhibitor therapy. Ann Oncol. 2020; 31(9):1207-1215.
  2. Igel LI, Kumar RB, Saunders KH, Aronne LJ. Practical Use of Pharmacotherapy for Obesity. Gastroenterology 2017; 152: 1765–1779.
  3. Apovian CM, Aronne LJ, Bessesen DH et al. Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015; 100: 342–362.
  4. Holst JJ. Incretin therapy for diabetes mellitus type 2. Curr Opin Endocrinol Diabetes Obes. 2020 Feb;27(1):2-10.
  5. Low PA, Singer W. Management of neurogenic orthostatic hypotension: an update. Lancet Neurol 2008; 7: 451–458.
  6. Cohen B, DeJong JM. Meclizine and placebo in treating vertigo of vestibular origin. Relative efficacy in a double-blind study. Arch Neurol 1972; 27: 129–135.
  7. Chobanian AV, Volicer L, Tifft CP et al. Mineralocorticoid-induced hypertension in patients with orthostatic hypotension. N Engl J Med 1979; 301: 68–73.
  8. Davies IB, Bannister RG, Sever PS, Wilcox CS. Fludrocortisone in the treatment of postural hypotension: altered sensitivity to pressor agents [proceedings]. Br J Clin Pharmacol 1978; 6: 444P–445P.
  9. Lanier JB, Mote MB, Clay EC. Evaluation and management of orthostatic hypotension. Am Fam Physician 2011; 84: 527–536.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.